English

Pipeline

Our pipeline holds proprietary clinical-stage assets and projects in the preclinical and research phases, all aimed at developing and commercializing applications arising from our unique technology platform.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Start » Pipeline » FG002

Pipeline

FG002

In FG002, a uPAR targeted IRDye® 800CW infrared dye.

A novel fluorophore that has been tested in clinical trials and that, due to its brightness, enables deep visibility into specific tissues. FluoGuide has entered into an agreement to develop uPAR targeted products to guide oncology surgery with LI-COR’s Biosciences, the company supplying this proprietary next-generation fluorophore to FluoGuide. IRDye 800CW possesses some unique features, such as deep tissue targeting, making it a highly relevant fluorophore to combine with FluoGuide’s uPAR binding molecule technology.